A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age

Summary

This study aims to assess the immune response and safety of GSK's candidate chickenpox and marketed MMR vaccines when given to children 12 to 15 months of age via a muscle injection. It compares the GSK vaccines to Merck's chickenpox vaccine, administered just under the skin. Additionally, the study will evaluate the immune response and safety of giving the GSK vaccines along with other childhood vaccines through a muscle injection.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Chickenpox

Eligibility basics and study details

Study type

Interventional

Phase

Phase 3

Ages

12 to 15 months

Sex

All

Healthy volunteers

Accepted

Sponsor

GlaxoSmithKline

Last updated on ClinicalTrials.gov

May 29, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites